FDA approves new treatment for hospital-acquired and ventilator-associated bacterial pneumonia

FDA today approved a new indication for the previously FDA-approved drug, Zerbaxa (ceftolozane and tazobactam) for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in patients 18 years and older.

Source: FDA Center for Drug Evaluation and Research - What's New - June 4, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news